Payment overview · 2025
General Payments
$3,408.81
171 reported records · 28 companies
Healthcare provider profile · identity verified
Mark A Testa, DO
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1043205370
Verified facts
What the public records show
CMS Open Payments records show Mark A Testa, DO received $3,408.81 in general payments during 2025 across 171 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ingrezza, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $460.98 | 13.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $407.09 | 11.9% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $352.92 | 10.3% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $319.63 | 9.4% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $252.09 | 7.4% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.19 | 5.4% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.91 | 5.0% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $169.46 | 5.0% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $165.67 | 4.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $120.34 | 3.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $96.98 | 2.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $94.01 | 2.8% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $74.65 | 2.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $67.41 | 2.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $63.18 | 1.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $60.56 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.39 | 1.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.02 | 1.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.69 | 1.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $37.79 | 1.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.02 | 0.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.42 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.75 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.74 | 0.8% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $22.37 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.99 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.22 | 0.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.34 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,408.81 | 171 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $375.13 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $335.95 | 21 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $270.10 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $252.09 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $248.83 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $219.17 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $169.46 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.44 | 14 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $165.67 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $145.83 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.56 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $132.02 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $120.34 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $94.01 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $90.38 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.06 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.84 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $74.65 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $67.41 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $63.18 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $60.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $50.64 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.18 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.50 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.20 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.20 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.70 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.70 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 190 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 25 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1298 | 324 |
| Atorvastatin Calcium | Atorvastatin Calcium | 847 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 821 | 190 |
| Alprazolam | Alprazolam | 689 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 140 |
| Losartan Potassium | Losartan Potassium | 593 | 148 |
| Lisinopril | Lisinopril | 576 | 142 |
| Omeprazole | Omeprazole | 544 | 138 |
| Gabapentin | Gabapentin | 534 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 530 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 443 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 354 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 340 | 102 |
| Ibuprofen | Ibuprofen | 326 | 98 |
| Famotidine | Famotidine | 312 | 97 |
| Furosemide | Furosemide | 308 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 70 |
| Metformin Hcl | Metformin Hcl | 300 | 78 |
| Simvastatin | Simvastatin | 284 | 74 |
| Lorazepam | Lorazepam | 281 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 276 | 88 |
| Metformin Hcl Er | Metformin Hcl | 273 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 267 | 69 |
| Trazodone Hcl | Trazodone Hcl | 266 | 65 |
| Carvedilol | Carvedilol | 235 | 53 |
| Tramadol Hcl | Tramadol Hcl | 231 | 55 |
| Amoxicillin | Amoxicillin | 225 | 153 |
| Clonazepam | Clonazepam | 220 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 218 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 212 | 38 |
| Montelukast Sodium | Montelukast Sodium | 209 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 203 | 22 |
| Sertraline Hcl | Sertraline Hcl | 200 | 40 |
| Ozempic | Semaglutide | 190 | 36 |
| Eliquis | Apixaban | 180 | 41 |
| Baclofen | Baclofen | 178 | 54 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 177 | 33 |
| Azithromycin | Azithromycin | 175 | 130 |
| Finasteride | Finasteride | 172 | 36 |
| Mirtazapine | Mirtazapine | 167 | 33 |
| Ezetimibe | Ezetimibe | 153 | 42 |
| Diazepam | Diazepam | 147 | 24 |
| Prednisone | Prednisone | 147 | 105 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 27 |
| Jardiance | Empagliflozin | 140 | 33 |
| Allopurinol | Allopurinol | 135 | 38 |
| Donepezil Hcl | Donepezil Hcl | 135 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 31 |
| Glimepiride | Glimepiride | 128 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 25 |
| Nifedipine Er | Nifedipine | 108 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 21 |
| Glipizide Er | Glipizide | 104 | 24 |
| Alendronate Sodium | Alendronate Sodium | 102 | 26 |
| Meclizine Hcl | Meclizine Hcl | 101 | 32 |
| Atenolol | Atenolol | 99 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 99 | 33 |
| Meloxicam | Meloxicam | 99 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 22 |
| Bupropion Xl | Bupropion Hcl | 89 | 20 |
| Valsartan | Valsartan | 86 | 19 |
| Lovastatin | Lovastatin | 83 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 20 |
| Naproxen | Naproxen | 82 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 16 |
| Potassium Chloride | Potassium Chloride | 78 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 74 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 17 |
| Pregabalin | Pregabalin | 72 | 11 |
| Glipizide | Glipizide | 66 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 64 | 15 |
| Valacyclovir | Valacyclovir Hcl | 62 | 32 |
| Enalapril Maleate | Enalapril Maleate | 61 | 12 |
| Irbesartan | Irbesartan | 61 | 14 |
| Synthroid | Levothyroxine Sodium | 59 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 58 | 13 |
| Januvia | Sitagliptin Phosphate | 57 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 14 |
| Farxiga | Dapagliflozin Propanediol | 55 | 14 |
| Lansoprazole | Lansoprazole | 54 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 27 |
| Linzess | Linaclotide | 50 | 11 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 14 |
| Testosterone | Testosterone | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Hydrocortisone | Hydrocortisone | 42 | 21 |
| Spironolactone | Spironolactone | 42 | 15 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Lactulose | Lactulose | 41 | 16 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 12 |
| Loperamide | Loperamide Hcl | 39 | suppressed |
| Ramipril | Ramipril | 39 | 11 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 12 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Methimazole | Methimazole | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 26 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Colchicine | Colchicine | 30 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 13 |
| Ingrezza | Valbenazine Tosylate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,408.81 · 171 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, INGREZZA, INSPIRE, JARDIANCE, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error